IRulya Therapeutics Inc. (IRLA) income statement
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$39.88−0.06 (-0.15%)
Close on Nov 20, 2026Market cap $40.56MP/E –Yield –
IRulya Therapeutics Inc. financial ratios
See a number that looks wrong?